SEC Form 4/A · accession 0001140361-16-090147
AVADEL PHARMACEUTICALS PLC · AVDL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Scott A. Macke
Officer — See Remarks
Period of report
Dec 14, 2016
Accepted (ET)
Dec 16, 2016 · 9:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001012477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ADSsF1,F2 | Dec 14, 2016 | A | 10,000 | — | A | 52,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F7 | $10.40 | Dec 14, 2016 | A | 65,000 | A | — | Dec 14, 2026 | ADSs | 65,000 | 65,000 | D |
| Stock Option (right to buy)F3 | $4.07 | holding | — | — | — | — | Feb 1, 2023 | ADSs | 7,500 | 7,500 | D |
| Stock Option (right to buy)F4 | $7.36 | holding | — | — | — | — | Dec 12, 2023 | ADSs | 20,000 | 20,000 | D |
| Stock Option (right to buy)F5 | $16.30 | holding | — | — | — | — | Dec 11, 2024 | ADSs | 50,000 | 50,000 | D |
| Stock Option (right to buy)F6 | $14.35 | holding | — | — | — | — | Dec 10, 2025 | ADSs | 35,000 | 35,000 | D |
Explanation of responses
- F1The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value 0.122 Euros per share, of the issuer; ADSs are represented by American Depositary Receipts. The securities acquired as reported in this statement represent the grant of ADSs under the issuer's "Free Share" award program; no purchase price was applicable to such grant. See footnote (2) for details as to the dates such ADSs will be issued to the reporting person.
- F2Includes (a) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/12/2013, all of which will be issued to the reporting person on the fourth anniversary of the grant date; (b) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/11/2014, all of which will be issued to the reporting person on the fourth anniversary of the grant date; (c) 15,000 restricted ADSs granted under the issuer's "Free Share" award program on 8/10/2016, all of which will be issued to the reporting person on the second anniversary of the grant date; and (d) 10,000 restricted ADSs granted under the issuer's "Free Share" award program on 12/14/2016, all of which will be issued to the reporting person on the second anniversary of the grant date.
- F3Options become exercisable as to 1,875 ADSs on each of the first four anniversaries after the 02/01//2013 grant date.
- F4Options become exercisable as to 5,000 ADSs on each of the first four anniversaries after the 12/12/2013 grant date.
- F5Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 12/11/2014 grant date.
- F6Options become exercisable as to 8,750 ADSs on each of the first four anniversaries after the 12/10/2015 grant date.
- F7Options become exercisable as to 16,250 ADSs on each of the first four anniversaries after the 12/14/2016 grant date.
Remarks
VP, Supply Chain & Operations Explanatory Note: This amendment is being filed to correct technical errors in the original filing caused by third party software. These errors resulted in the transactions and holdings appearing as a duplication of the transactions and holdings reported on a separate Form 4 filed on the date hereof by the individual who signed the original report as attorney-in-fact.